8-K: Butterfly Network Achieves Record Revenue and Gross Margins, Announces CFO Transition Amid Strong Q2 Performance

Butterfly Network reported its highest quarterly revenue and gross margins in company history for Q2 2025, alongside a significant reduction in cash usage and the departure of its Chief Financial and Operations Officer.

Summary

• Total revenue for Q2 2025 reached $23.4 million, marking a 9% year-over-year increase from $21.5 million in Q2 2024, representing the highest quarterly revenue in company history.
• Gross margin improved to a record 63.7% in Q2 2025, up from 58.6% in the prior year period, primarily due to higher average selling prices and improved software and other services margins.
• Net loss for Q2 2025 was $13.8 million, an improvement from $15.7 million in Q2 2024.
• Adjusted EBITDA loss significantly narrowed to $6.2 million in Q2 2025, compared to $8.1 million in Q2 2024.
• Quarterly cash used was reduced to $7.1 million, the lowest in any quarter for the company.
• Cash and cash equivalents stood at $148.1 million as of June 30, 2025.
• The company revised its full-year 2025 revenue guidance to $91 million to $95 million (approximately 13% growth) and improved its Adjusted EBITDA loss guidance to $32 million $37 million.
• Heather Getz, Executive Vice President and Chief Financial & Operations Officer, resigned effective August 1, 2025, to pursue other interests, with her departure not related to any disagreements on accounting or operations.
• Megan Carlson, Chief Accounting Officer and Senior Vice President of Finance & Accounting, has been appointed Interim Chief Financial Officer, effective August 1, 2025.
• Strategic highlights include adding two new partners to Butterfly Garden, three existing partners receiving FDA clearance for AI-powered clinical applications (iCardio, HeartFocus by DESKi, Deep Echo), and the upcoming launch of Compass AI software in Q3.
• The Butterfly HomeCare pilot program concluded successfully, demonstrating meaningful reductions in readmissions for congestive heart failure patients, with a first commercial agreement expected by year-end.

Sentiment

Score: 8

Explanation: The filing presents strong positive financial results, including record revenue and gross margins, significantly reduced cash burn, and improved profitability metrics. Strategic initiatives like AI integration and HomeCare progress are promising. The CFO transition is handled smoothly with an experienced interim replacement, and the company's guidance for the full year is improved. The overall tone and content indicate a positive trajectory and operational discipline.

Positives

• Achieved highest quarterly revenue in company history at $23.4 million, representing 9% year-over-year growth.
• Reached record gross margins of 64%, indicating improved profitability and cost management.
• Reduced quarterly cash used to $7.1 million, the lowest of any quarter, demonstrating increased financial discipline.
• Net loss improved to $13.8 million from $15.7 million in the prior year period.
• Adjusted EBITDA loss improved to $6.2 million from $8.1 million in the prior year period.
• Adjusted EPS improved to $(0.03) from $(0.05) in the prior year period.
• Revised full-year revenue guidance to $91 million to $95 million (approximately 13% growth) and improved Adjusted EBITDA loss guidance to $32 million $37 million.
• Expanded Butterfly Garden with two new partners and secured FDA clearance for three AI-powered clinical applications from existing partners.
• Successfully concluded the Butterfly HomeCare pilot program, showing meaningful reductions in readmissions for congestive heart failure patients, with a commercial agreement anticipated by year-end.
• Expected launch of Compass AI, a next-generation cloud-based enterprise software platform, in Q3 to optimize documentation processes with advanced AI tools.

Negatives

• U.S. revenue remained essentially flat year-over-year at $17.2 million, partially offset by lower probe sales volume.
• Operating expenses increased by 4% to $31.0 million compared to the prior year period.

Risks

• Ability to grow and manage growth effectively.
• Success, cost, and timing of product and service development activities.
• The degree to which products and services are accepted by healthcare practitioners and patients for their approved uses.
• Ability to obtain and maintain regulatory approval for products, and any related restrictions and limitations on the use of any authorized product.
• Ability to identify, in-license, or acquire additional technology.
• Ability to maintain existing license, manufacturing, supply, and distribution agreements.
• Ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources.
• Changes in applicable laws or regulations.
• The size and growth potential of the markets for products and services, and ability to serve those markets.
• The pricing of products and services, and reimbursement for medical procedures conducted using products and services.
• Estimates regarding expenses, revenue, capital requirements, and needs for additional financing.
• Financial performance.
• Ability to attract and retain customers.
• Ability to manage growth effectively.
• Ability to protect or enforce intellectual property rights.
• Ability to maintain the listing of Class A common stock on the New York Stock Exchange.

Future Outlook

The company remains focused on scaling its core business and unlocking new revenue streams by leveraging existing technology. It anticipates handheld ultrasound becoming a foundational part of care delivery. Upcoming developments include the launch of Compass AI software in Q3, the P5 chip, and fourth-generation technology on the horizon. The company aims to continue innovating across hardware and software to expand adoption and maximize platform value, with a goal of deploying the Butterfly HomeCare solution in a partner's first state before the end of the year.

Management Comments

• "Quarter 2 marked one year since we launched Butterfly iQ3, and I'm pleased to say we achieved a new high – our strongest revenue quarter in Company history at $23.4 million. We also reached record gross margins of 64% and had our lowest cash use yet at $7.1 million. It's a real testament to the discipline of our team and the strength of our multi-pronged strategy – especially as we continue pushing toward breakeven in a challenging macro environment."
• "As we look ahead, we remain focused on scaling our core business, while unlocking new revenue streams by leveraging our existing technology. Handheld ultrasound is becoming a foundational part of care delivery, and with our Compass AI software coming soon, as well as our P5 chip and fourth-generation technology on the horizon, we're poised to continue leading that shift. We will continue innovating across hardware and software to expand adoption and maximize the value of the platform we've built."
• "On behalf of our employees and Board of Directors, I want to thank Heather for her more than three years of dedicated service. We value the discipline she instilled across the organization, and under her leadership Butterfly strengthened its balance sheet and delivered on its financial commitments to shareholders. We wish her every success in her future endeavors."
• "I have the utmost confidence in Megan's ability to lead our finance organization and ensure a seamless transition. Megan's experience and deep understanding of our financial operations will be instrumental as we enter a new chapter for the company."
• "It has been a privilege to serve on Butterfly's leadership team, and I am proud of our accomplishments during my tenure. The dedicated team at Butterfly is well-positioned to continue executing on its strategic vision to create shareholder value."

Industry Context

This announcement highlights Butterfly Network's continued progress in the digital health and medical imaging sectors, particularly in portable ultrasound technology. The focus on AI-powered clinical applications and enterprise software platforms like Compass AI aligns with broader industry trends towards integrating artificial intelligence for enhanced diagnostics, workflow optimization, and data management in healthcare. The successful HomeCare pilot program also reflects the growing emphasis on remote patient monitoring and decentralized care models, leveraging technology to improve patient outcomes and reduce healthcare costs. The development of next-generation chip technology (P5) and fourth-generation devices indicates a commitment to innovation in a competitive market for medical devices and health tech.

Comparison to Industry Standards

• The company's achievement of record gross margins at 64% is a strong indicator of efficiency, especially when compared to traditional medical device manufacturers that may have lower software-driven margins. While specific comparable companies are not named in the filing, this margin level suggests a favorable position within the digital health and software-as-a-service (SaaS) segments of the healthcare industry.
• The successful pilot program for Butterfly HomeCare, demonstrating meaningful reductions in readmissions for congestive heart failure patients, positions the company favorably against competitors in the remote patient monitoring and value-based care space. This outcome suggests the potential for significant cost savings for healthcare systems, a key metric for adoption in the current healthcare environment.
• The FDA clearances for AI-powered clinical applications from partners like iCardio, HeartFocus by DESKi, and Deep Echo, and the development of Compass AI, indicate the company's commitment to integrating advanced AI into its platform. This aligns with leading medical technology companies that are increasingly leveraging AI to enhance diagnostic accuracy and operational efficiency, such as GE HealthCare's AI-powered ultrasound solutions or Philips' AI-driven diagnostic platforms.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to record revenue and gross margins, reduced cash burn, improved profitability, and positive revised guidance. The CFO transition is managed to ensure continuity.
• Employees: Megan Carlson's internal promotion to Interim CFO provides continuity and recognition of internal talent. Heather Getz's advisory role ensures a smooth transition.
• Customers: New AI-powered clinical applications (iCardio, HeartFocus, Deep Echo) and the upcoming Compass AI software are expected to enhance the utility and efficiency of Butterfly devices, improving the customer experience. New educational resources also benefit users.
• Partners: Continued growth of the 'Butterfly Garden' with new partners and FDA clearances for partner AI applications indicates a healthy ecosystem and potential for expanded collaborations.

Next Steps

• HeartFocus by DESKi expects to launch to Butterfly users in Q3 2025, with iCardio and Deep Echo launching shortly thereafter.
• Compass AI, the next-generation cloud-based enterprise software platform, is expected to launch in Q3 2025.
• Full findings from the Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital study are accepted into a prominent medical journal for publication in Q3 2025.
• The company and its partner are working toward completion of their first commercial agreement for Butterfly HomeCare, aiming to deploy the solution in the partner's first state before the end of 2025.
• The company has commenced a search for a permanent Chief Financial Officer.
• Development of the P5 chip and fourth-generation technology is on the horizon.

Key Dates

Recommendation

The filing demonstrates strong operational and financial improvements, including record revenue and gross margins, significantly reduced cash burn, and improved profitability metrics (net loss, Adjusted EBITDA, Adjusted EPS). The company also provided improved full-year guidance. Strategic initiatives like the expansion of AI-powered applications and the progress of the HomeCare solution indicate a clear path for future growth and market penetration. While a CFO transition is occurring, it appears well-managed with an experienced internal appointment, and the stated reason for departure is not related to financial discrepancies. These factors collectively suggest a positive outlook and strong potential for value creation.

Keywords

Ultrasound, Digital Health, Medical Imaging, AI in Healthcare, Portable Ultrasound, Semiconductor Technology, Financial Results, Q2 2025, Revenue Growth, Gross Margin, Cash Flow, CFO Transition, Corporate Governance, FDA Clearance, HomeCare, Compass AI, BFLY